Ketamine Therapy Statistics & Facts (2026)

A citable, physician-maintained reference of the key numbers behind ketamine therapy in 2026. Every statistic below links to its primary source, a peer-reviewed study or our own verified pricing, so you can check it rather than take it on faith. If you are writing about ketamine and need a number you can stand behind, this page is built to be quoted. For the underlying studies in full, see the ketamine research and evidence hub.

Efficacy statistics

• 50–70% — response rate for ketamine in treatment-resistant depression, meaning patients who had already failed conventional antidepressants. Confirmed across randomized trials and real-world meta-analysis. (Murrough 2013; Alnefeesi 2022 real-world meta-analysis)
• Within hours — how fast ketamine can reduce depressive symptoms and suicidal ideation, versus the 4–6 weeks typical of SSRIs. This speed is ketamine's defining clinical feature. (Wilkinson 2018, individual-participant-data meta-analysis)
• 2006 — the year of the landmark randomized controlled trial that established ketamine's rapid antidepressant effect in treatment-resistant depression, making this one of psychiatry's most-replicated modern findings. (Zarate 2006)

Statistics by condition

• PTSD: ketamine significantly reduced symptoms in randomized controlled trials of chronic post-traumatic stress disorder — PTSD is an indication, not a contraindication. (Feder 2014; Feder 2021 repeated dosing)
• Anxiety: meta-analysis of randomized controlled trials found a significant dose-related effect for ketamine in refractory anxiety-spectrum disorders. (Whittaker 2021)
• Bipolar depression: randomized add-on trials show benefit in treatment-resistant bipolar depression for patients maintained on mood stabilizers (with careful screening for mania risk). (Diazgranados 2010)
• Alcohol use disorder: a single ketamine infusion combined with psychological therapy improved outcomes in randomized trials — an emerging but real signal. (Grabski 2022)

Cost statistics (2026, US)

• $129/month — the cheapest legitimate at-home option (Joyous, daily low-dose model).
• $250/month — lowest-cost physician-led, session-based at-home program (Discreet Ketamine; medication billed separately).
• $400–$800 per session — typical in-clinic IV ketamine infusion.
• $600–$900 per session — Spravato (esketamine), the one route with reliable insurance coverage.
• Full provider-by-provider breakdown: 2026 ketamine therapy cost comparison.

Eligibility and safety statistics

• ~85–90% — share of adults who apply to a reputable at-home ketamine program and are medically cleared after intake screening; the true contraindications are a short, well-defined list.
• Mild and transient — the systematic-review characterization of side effects at supervised therapeutic psychiatric doses. (Short 2018)
• Chronic high-dose only — the serious urinary toxicity (ketamine cystitis) associated with ketamine is a phenomenon of chronic recreational use, first described in 2007, not of supervised intermittent therapy. (Shahani 2007)
• Benzodiazepines blunt the effect — concomitant benzodiazepine use is associated with a reduced antidepressant response to ketamine, an interaction patients are rarely warned about. (Feeney 2022, RAPID study)

Mechanism and regulatory facts

• Synaptogenesis, not serotonin — ketamine's antidepressant effect works through mTOR-dependent synapse formation (neuroplasticity), a fundamentally different mechanism than SSRIs, which explains both its speed and its durability. (Li 2010, Science)
• 2019 — the year the FDA approved esketamine (Spravato) nasal spray for treatment-resistant depression. It remains the only FDA-approved ketamine-class product for psychiatric use.
• Off-label — compounded racemic ketamine (the form used in most at-home and IV-clinic programs) is prescribed off-label for depression, anxiety, PTSD, and chronic pain. Off-label prescribing is legal and evidence-based but is not the same as FDA approval.

Frequently Asked Questions

What percentage of people respond to ketamine for depression?

Roughly 50–70% of patients with treatment-resistant depression respond to ketamine, based on randomized controlled trials and real-world meta-analysis (Murrough 2013; Alnefeesi 2022). This is notable because the population is defined by having already failed other antidepressants. A meaningful minority do not respond.

How fast does ketamine work compared to antidepressants?

Ketamine can produce a measurable antidepressant effect within hours, versus the four to six weeks typical of SSRIs (Wilkinson 2018). The rapid reduction of suicidal ideation specifically is its most clinically important property.

How much does ketamine therapy cost in 2026?

At-home programs range from about $129/month (Joyous) to $250/month (Discreet Ketamine, physician-led), in-clinic IV runs $400–$800 per session, and Spravato is $600–$900 per session but is often insurance-covered. See the full cost comparison.

Is ketamine FDA-approved?

Only esketamine (Spravato) is FDA-approved, since 2019, for treatment-resistant depression. Compounded racemic ketamine is prescribed off-label, which is legal and evidence-based but not FDA-approved for psychiatric use.

Dr. Ben Soffer, DO — board-certified physician. This is a maintained statistics reference, updated as new data publishes. Each figure links to its primary source; please cite the original study or this page when reusing these numbers.